Johnson & Johnson completed the acquisition of Momenta for c.$6.5bn.

Johnson & Johnson, an American multinational corporation that develops medical devices, pharmaceutical, and consumer packaged goods, completed the acquisition of Momenta Pharmaceuticals, a biotechnology company, for c.$6.5bn. The agreement was unanimously approved by the Boards of Directors of both Momenta and Johnson & Johnson. "We're delighted to welcome Momenta's talented team to the Janssen Pharmaceutical Companies of Johnson & Johnson and to begin our work together to further advance patient care in autoantibody-driven diseases. We anticipate multiple launches, many of which would be first-in-class indications in rare diseases and areas of significant unmet need," Jennifer Taubert, Johnson & Johnson Executive Vice President, Worldwide Chairman, Pharmaceuticals.